Voyager Therapeutics, Inc. (VYGR) Dividend History

Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing gene therapies for neurological diseases. Utilizing its proprietary AAV (adeno-associated virus) platform, Voyager aims to deliver potentially one-time treatments for conditions such as Parkinson's disease, Rett syndrome, and other neurodegenerative disorders. The company emphasizes innovative approaches to develop therapies that can modify disease progression and improve patient outcomes.

75 Hayden Avenue, Lexington, MA, 02421
Phone: 857-259-5340
Website: https://www.voyagertherapeutics.com

Dividend History

Voyager Therapeutics, Inc. currently does not pay dividends

Company News

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Voyager Therapeutics published data in Molecular Therapy demonstrating the ability of a novel AAV capsid, VCAP-102, to cross the blood-brain barrier and transduce various brain regions in rodents and non-human primates. The company also highlighted its next-generation CNS capsids and non-viral delivery approaches.

GlobeNewswire Inc.
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

Voyager Therapeutics presented new preclinical data on its tau-targeting gene therapy VY1706 and anti-tau antibody VY7523 at the AD/PD™ 2025 conference. The data showed promising results in reducing tau levels and inhibiting tau spread in animal models, supporting the potential of these programs for the treatment of Alzheimer's disease.

GlobeNewswire Inc.
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Voyager Therapeutics reported progress in its tau silencing gene therapy VY1706 and anti-tau antibody VY7523 programs for Alzheimer's disease. The company also extended its cash runway into mid-2027 by discontinuing its VY9323 program for ALS.

GlobeNewswire Inc.
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors

Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (VYGR) due to emerging preclinical data indicating the siRNA payload component of VY9323 does not meet the company's standards, resulting in a narrowed therapeutic window and the decision to not file an IND application for VY9323 in mid-2025.

GlobeNewswire Inc.
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Voyager Therapeutics, a biotechnology company, announced its participation in several upcoming investor conferences, including discussions on genetic medicines and fireside chats.

GlobeNewswire Inc.

Featured Companies: NBIX SGMO

Dividend data last updated 06/06/2025 21:29:05 UTC